There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cocrystal Pharma (COCP – Research Report) and iTeos Therapeutics (ITOS – Research Report) with bullish sentiments.
Cocrystal Pharma (COCP)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cocrystal Pharma today and set a price target of $4.00. The company’s shares closed last Wednesday at $0.58, close to its 52-week low of $0.45.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cocrystal Pharma with a $4.50 average price target.
iTeos Therapeutics (ITOS)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on iTeos Therapeutics today and set a price target of $54.00. The company’s shares closed last Wednesday at $31.92.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for iTeos Therapeutics with a $54.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on COCP:
- Dollar General Updates 1 Key Risk Factor
- H.C. Wainwright Keeps Their Buy Rating on Context Therapeutics (CNTX)
- H.C. Wainwright Thinks Mogo Finance Technology’s Stock is Going to Recover
- Renesola (SOL) Receives a Rating Update from a Top Analyst
- H.C. Wainwright Keeps a Buy Rating on Golden Minerals Co (AUMN)